Phase II trial of VX 135 + daclatasvir in patients with genotype 1, 2 or 3 hepatitis C infection.
Latest Information Update: 09 Apr 2013
At a glance
- Drugs Daclatasvir (Primary) ; VX 135 (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 09 Apr 2013 New trial record
- 05 Apr 2013 This trial is expected to be initiated in the second half of 2013, according to a Vertex Pharmaceuticals media release.